Biological therapies for asthma
Five to 10% of asthma patients remain symptomatic and/or have asthma attacks despite adequate inhaled and systemic therapy. Eosinophilic, type 2 airway inflammation is seen in half of these patients with severe asthma. There is now convincing evidence that type 2 inflammation drives susceptibility t...
| প্রধান লেখক: | , |
|---|---|
| অন্যান্য লেখক: | |
| বিন্যাস: | Book section |
| ভাষা: | English |
| প্রকাশিত: |
Elsevier
2021
|
| সংক্ষিপ্ত: | Five to 10% of asthma patients remain symptomatic and/or have asthma attacks despite adequate inhaled and systemic therapy. Eosinophilic, type 2 airway inflammation is seen in half of these patients with severe asthma. There is now convincing evidence that type 2 inflammation drives susceptibility to asthma attacks and is associated with a good response to biological therapies. Monoclonal antibodies targeting immunoglobulin E, interleukin (IL)-5 and IL-4/13 now have established efficacy in severe type 2 asthma. Novel alarmin-blocking and crystal-dissolving therapies are promising. Prescribing biologics, weaning steroids and treating subsequent exacerbations are rapidly evolving clinical challenges. |
|---|